REFERENCES
1. McCrindle BW, Rowley AH, Newburger JW, et al.; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927-99.
2. Wang Q, Li W, Wan J, et al. Electrocardiographic alterations combined with hematological, biochemical, and metabolic profiles predict prognosis in Kawasaki disease. J Cardiovasc Dev Dis. 2026;13:228.
3. Eleftheriou D, Moraes YC, Purvis C, et al. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol. Trials. 2023;24:60.
4. Zheng X, Li J, Yue P, et al. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease? - Current evidence based on a meta-analysis. PLoS One. 2021;16:e0248812.
5. Watanabe M, Fukazawa R, Kiriyama T, et al. Hemodynamic evaluation of coronary artery lesions after Kawasaki disease: comparison of fractional flow reserve during cardiac catheterization with myocardial flow reserve during 13N-ammonia PET. J Cardiovasc Dev Dis. 2024;11:229.
6. Amorim-Figueiredo R, Pereira Lemos A, Rito T, Conde M, Brito MJ, Pinto F. Multiresistant Kawasaki disease in a young infant with giant aneurysms growing fast. J Cardiovasc Dev Dis. 2024;11:149.
7. Burns JC, Koné-Paut I, Kuijpers T, Shimizu C, Tremoulet A, Arditi M. Review: Found in translation: international initiatives pursuing interleukin-1 blockade for treatment of acute Kawasaki disease. Arthritis Rheumatol. 2017;69:268-76.
8. Atici AE, Noval Rivas M, Arditi M. The central role of interleukin-1 signalling in the pathogenesis of Kawasaki disease vasculitis: path to translation. Can J Cardiol. 2024;40:2305-20.
9. Zhang R, Zhang J, Yang Y, Wang Y, Cao H. The autophagy-inflammasome axis as a molecular switch: from persistent inflammation to vascular remodeling in IVIG-resistant Kawasaki disease. Int J Mol Sci. 2026;27:6405.
10. Suganuma E, Sato S, Honda S, Nakazawa A. A novel mouse model of coronary stenosis mimicking Kawasaki disease induced by Lactobacillus casei cell wall extract. Exp Anim. 2020;69:233-41.
11. Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol. 2020;16:391-405.
12. Lee Y, Schulte DJ, Shimada K, et al. Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation. 2012;125:1542-50.
13. Gorelik M, Lee Y, Abe M, et al. IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis. Clin Exp Immunol. 2019;198:101-10.
14. Koné-Paut I, Tellier S, Belot A, et al. Phase II open label study of anakinra in intravenous immunoglobulin-resistant Kawasaki disease. Arthritis Rheumatol. 2021;73:151-61.
15. Kessel C, Koné-Paut I, Tellier S, et al. An immunological axis involving interleukin 1β and leucine-rich-α2-glycoprotein reflects therapeutic response of children with Kawasaki disease: implications from the KAWAKINRA trial. J Clin Immunol. 2022;42:1330-41.
16. Yang J, Jain S, Capparelli EV, et al. Anakinra treatment in patients with acute Kawasaki disease with coronary artery aneurysms: a phase I/IIa trial. J Pediatr. 2022;243:173-80.e8.
17. Xu Q, Wu Y, Ding Y. The autophagy-inflammation axis in Kawasaki disease: pathogenic mechanisms and translational opportunities. J Clin Med. 2026;15:3918.
18. Lin M, Xian H, Chen Z, et al. MCM8-mediated mitophagy protects vascular health in response to nitric oxide signaling in a mouse model of Kawasaki disease. Nat Cardiovasc Res. 2023;2:778-92.
19. Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401-14.
20. Gupta S, Cassel SL, Sutterwala FS, Dagvadorj J. Regulation of the NLRP3 inflammasome by autophagy and mitophagy. Immunol Rev. 2025;329:e13410.
21. Marek-Iannucci S, Ozdemir AB, Moreira D, et al. Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis. JCI Insight. 2021;6:e151981.
22. Mouton-Liger F, Rosazza T, Sepulveda-Diaz J, et al. Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop. Glia. 2018;66:1736-51.
23. Jankauskas SS, Mone P, Avvisato R, et al. miR-181c targets Parkin and SMAD7 in human cardiac fibroblasts: validation of differential microRNA expression in patients with diabetes and heart failure with preserved ejection fraction. Mech Ageing Dev. 2023;212:111818.
24. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434:113-8.
25. Jankauskas SS, Mone P, Santulli G. From resveratrol to ISIDE11: how to activate SIRT1 and improve endothelial function? New therapeutic insights for methylenetetrahydrofolate reductase deficiency. Cell Mol Life Sci. 2022;79:451.
26. Ding YN, Wang HY, Chen XF, Tang X, Chen HZ. Roles of Sirtuins in cardiovascular diseases: mechanisms and therapeutics. Circ Res. 2025;136:524-50.
27. Ministrini S, Puspitasari YM, Beer G, Liberale L, Montecucco F, Camici GG. Sirtuin 1 in endothelial dysfunction and cardiovascular aging. Front Physiol. 2021;12:733696.
28. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27:513-28.
29. Kansakar U, Jankauskas SS, Gambardella J, Santulli G. Targeting the phenotypic switch of vascular smooth muscle cells to tackle atherosclerosis. Atherosclerosis. 2021;324:117-20.
30. Atici AE, Jena PK, Carvalho TT, et al. Sirtuin 1 activation mitigates murine vasculitis severity by promoting mitophagy. Circ Res. 2026;139:e327991.
31. Gottlieb RA, Andres AM, Sin J, Taylor DP. Untangling autophagy measurements: all fluxed up. Circ Res. 2015;116:504-14.
32. Khawaja RR, Griego E, Lindenau K, et al. Chaperone-mediated autophagy regulates neuronal activity by sex-specific remodelling of the synaptic proteome. Nat Cell Biol. 2025;27:1688-707.
33. Gupta S, Afzal M, Agrawal N, et al. Harnessing the FOXO-SIRT1 axis: insights into cellular stress, metabolism, and aging. Biogerontology. 2025;26:65.
34. Wei X, Xiong X, Wang P, Zhang S, Peng D. SIRT1-mediated deacetylation of FOXO3 enhances mitophagy and drives hormone resistance in endometrial cancer. Mol Med. 2024;30:147.
35. Porritt RA, Markman JL, Maruyama D, et al. Interleukin-1 beta-mediated sex differences in Kawasaki disease vasculitis development and response to treatment. Arterioscler Thromb Vasc Biol. 2020;40:802-18.
36. Curry AM, White DS, Donu D, Cen Y. Human Sirtuin regulators: the “success” stories. Front Physiol. 2021;12:752117.
37. Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016;17:679-90.
38. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.
